About Icons

Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

[1] Anifrolumab (anifrolumab-fnia)

[1] Anifrolumab (Anifrolumab, Anifrolumab-fnia) 💬

[2] IFNAR1,
IFNAR2 💬

[18] Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬

[6] 46, 48, 49, 50, 51, 53 💬

2

Anifrolumab (MEDI-546)

[1] Anifrolumab (anifrolumab-fnia)

[1] Anifrolumab (Anifrolumab, Anifrolumab-fnia) 💬

[2] IFNAR1,
IFNAR2 💬

[18] Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬

[1] 46 💬

3

Anifrolumab 1000 mg

[1] Anifrolumab (anifrolumab-fnia)

[1] Anifrolumab (Anifrolumab, Anifrolumab-fnia) 💬

[2] IFNAR1,
IFNAR2 💬

[18] Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬

[1] 49 💬

4

Anifrolumab 300 mg

[1] Anifrolumab (anifrolumab-fnia)

[1] Anifrolumab (Anifrolumab, Anifrolumab-fnia) 💬

[2] IFNAR1,
IFNAR2 💬

[18] Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬

[1] 49 💬

5

Combination Product: Anifrolumab (blinded)

[1] Anifrolumab (anifrolumab-fnia)

[1] Anifrolumab (Anifrolumab, Anifrolumab-fnia) 💬

[2] IFNAR1,
IFNAR2 💬

[18] Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬

[2] 50, 51 💬

6

Combination Product: Anifrolumab (unblinded, open label)

[1] Anifrolumab (anifrolumab-fnia)

[1] Anifrolumab (Anifrolumab, Anifrolumab-fnia) 💬

[2] IFNAR1,
IFNAR2 💬

[18] Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬

[2] 50, 51 💬

7

Combination Product: Anifrolumab + APFS

[1] Anifrolumab (anifrolumab-fnia)

[1] Anifrolumab (Anifrolumab, Anifrolumab-fnia) 💬

[2] IFNAR1,
IFNAR2 💬

[18] Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬

[1] 49 💬